| Transaction Date | Insider | Title | Form | Trade Types | Δ Securities | Δ Cash | Owned |
---|
| 2025-01-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −400 | $21.6K | 55.59K |
| 2024-12-17 | Carey Stephen P. | SVP, CFO | 4 | S | −7,500 | $418.4K | 154.47K |
| 2024-12-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $14.1K | 55.99K |
| 2024-12-11 | Davis Krista | CHIEF HR OFFICER, SVP | 4 | S | −1,000 | $60K | 49.06K |
| 2024-11-26 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | M, S | −3,481 | $1.1M | 370.38K |
| 2024-11-15 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | S | −6,500 | $375.1K | 76.78K |
| 2024-11-15 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 4 | F | −867 | $0 | 33.17K |
| 2024-11-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $15.3K | 56.24K |
| 2024-10-14 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $14.3K | 56.49K |
| 2024-09-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $14.2K | 56.74K |
| 2024-09-12 | Davis Krista | CHIEF HR OFFICER, SVP | 4 | F | −1,486 | $0 | 50.06K |
| 2024-09-08 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | F | −3,646 | $0 | 373.86K |
| 2024-08-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $14.9K | 56.99K |
| 2024-07-18 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | F | −1,743 | $0 | 57.24K |
| 2024-07-18 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −2,743 | $170.1K | 706.27K |
| 2024-07-15 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −47,257 | $3M | 709.02K |
| 2024-07-12 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $16.2K | 58.98K |
| 2024-07-01 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | S | −20,000 | $1.3M | 242.91K |
| 2024-06-21 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −20,000 | $1.2M | 756.27K |
| 2024-06-17 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −30,000 | $1.8M | 776.27K |
| 2024-06-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $16K | 59.23K |
| 2024-06-07 | Marken James G. | PROD DEV, SVP OPS | 4 | F, M | 1,463 | -$661.4K | 117.83K |
| 2024-06-05 | Gutwerg Ori | SVP, GENERICS | 4 | S | −2,985 | $200K | 77.23K |
| 2024-06-04 | Carey Stephen P. | SVP, CFO | 4 | S | −5,000 | $317.9K | 161.97K |
| 2024-06-03 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | S | −20,000 | $1.3M | 262.91K |
| 2024-05-21 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | S | −2,000 | $123.2K | 83.28K |
| 2024-05-21 | Thoma Jeanne | Dir | 4 | A | 4,410 | $0 | 40.61K |
| 2024-05-21 | Leonard Matthew J | Dir | 4 | A | 4,410 | $0 | 11.99K |
| 2024-05-21 | Walsh Patrick D | Dir | 4 | A | 4,410 | $0 | 74.71K |
| 2024-05-21 | Pera Antonio R | Dir | 4 | A | 4,410 | $0 | 31.04K |
| 2024-05-21 | Tannenbaum Renee P | Dir | 4 | A | 4,410 | $0 | 22.62K |
| 2024-05-21 | Haughey Thomas | Dir | 4 | A | 4,410 | $0 | 51.53K |
| 2024-05-20 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −12,855 | $794.6K | 806.27K |
| 2024-05-16 | Tannenbaum Renee P | Dir | 4 | S | −2,000 | $127.7K | 18.21K |
| 2024-05-15 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −37,145 | $2.4M | 819.13K |
| 2024-05-14 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | S | −16,669 | $1.1M | 377.51K |
| 2024-05-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $16.9K | 59.48K |
| 2024-05-01 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | S | −20,000 | $1.3M | 282.91K |
| 2024-04-18 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −27,232 | $1.8M | 856.27K |
| 2024-04-15 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −22,768 | $1.5M | 883.5K |
| 2024-04-12 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $16.9K | 59.73K |
| 2024-04-10 | Carey Stephen P. | SVP, CFO | 4 | F | −4,534 | $0 | 166.97K |
| 2024-04-10 | Marken James G. | PROD DEV, SVP OPS | 4 | F | −2,799 | $0 | 116.01K |
| 2024-04-01 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | S | −20,000 | $1.3M | 302.91K |
| 2024-03-23 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | F | −17,455 | $0 | 394.17K |
| 2024-03-23 | Carey Stephen P. | SVP, CFO | 4 | F | −6,210 | $0 | 171.5K |
| 2024-03-23 | Marken James G. | PROD DEV, SVP OPS | 4 | F | −3,653 | $0 | 118.81K |
| 2024-03-18 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 3 | | 0 | $0 | 34.04K |
| 2024-03-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $16.6K | 59.98K |
| 2024-03-11 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | S | −20,000 | $1.3M | 322.91K |
| 2024-03-08 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −10,000 | $671.7K | 906.27K |
| 2024-03-07 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | F | −2,110 | $0 | 85.28K |
| 2024-03-07 | Gutwerg Ori | SVP, GENERICS | 4 | F | −2,494 | $0 | 80.21K |
| 2024-03-07 | Carey Stephen P. | SVP, CFO | 4 | F, S | −12,003 | $510.4K | 177.71K |
| 2024-03-07 | Marken James G. | PROD DEV, SVP OPS | 4 | F, S | −26,372 | $1.6M | 122.46K |
| 2024-03-06 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | F, S | −62,317 | $3M | 411.63K |
| 2024-03-05 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −40,000 | $2.6M | 916.27K |
| 2024-03-05 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | S | −5,000 | $330K | 87.39K |
| 2024-03-04 | Pera Antonio R | Dir | 4 | S | −7,000 | $456.4K | 26.63K |
| 2024-02-29 | Davis Krista | CHIEF HR OFFICER, SVP | 4 | F | −1,173 | $0 | 51.55K |
| 2024-02-29 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | F | −1,173 | $0 | 60.23K |
| 2024-02-29 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | F | −1,635 | $0 | 342.91K |
| 2024-02-29 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | F | −1,122 | $0 | 956.27K |
| 2024-02-29 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | F | −1,275 | $0 | 92.39K |
| 2024-02-29 | Gutwerg Ori | SVP, GENERICS | 4 | F | −1,570 | $0 | 82.71K |
| 2024-02-29 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | F | −10,014 | $0 | 473.95K |
| 2024-02-29 | Carey Stephen P. | SVP, CFO | 4 | F | −1,914 | $0 | 189.72K |
| 2024-02-29 | Marken James G. | PROD DEV, SVP OPS | 4 | F | −1,058 | $0 | 148.83K |
| 2024-02-15 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | F | −1,261 | $0 | 93.66K |
| 2024-02-15 | Gutwerg Ori | SVP, GENERICS | 4 | F | −1,244 | $0 | 84.28K |
| 2024-02-14 | Davis Krista | CHIEF HR OFFICER, SVP | 4 | A | 20,131 | $0 | 52.72K |
| 2024-02-14 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | A | 24,605 | $0 | 61.4K |
| 2024-02-14 | Gassert Chad | SVP - CORP. DEV., STRATEGY | 4 | A | 22,367 | $0 | 344.54K |
| 2024-02-14 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | A | 22,367 | $0 | 957.39K |
| 2024-02-14 | Mutz Christopher | HEAD OF RARE DISEASE | 4 | A | 31,316 | $0 | 94.92K |
| 2024-02-14 | Gutwerg Ori | SVP, GENERICS | 4 | A | 24,605 | $0 | 85.52K |
| 2024-02-14 | Lalwani Nikhil | PRESIDENT, CEO, Dir | 4 | A | 134,216 | $0 | 483.96K |
| 2024-02-14 | Carey Stephen P. | SVP, CFO | 4 | A | 35,790 | $0 | 191.63K |
| 2024-02-14 | Marken James G. | PROD DEV, SVP OPS | 4 | A | 16,776 | $0 | 149.89K |
| 2024-02-13 | Cook Meredith | SEC., SR. VP, GENERAL COUNSEL | 4 | S | −250 | $14K | 36.8K |
| 2024-01-19 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −25,216 | $1.4M | 935.03K |
| 2024-01-16 | Shanmugam Muthusamy | Dir, HEAD OF R&D, COO-NOVITIUM OPS | 4 | S | −24,784 | $1.4M | 960.24K |